pmc logo image
Logo of brjopthalBritish Journal of OphthalmologyCurrent TOCInstructions for authors

Formats:

Br J Ophthalmol. 2000 March; 84(3): 268–272.
doi: 10.1136/bjo.84.3.268.
PMCID: PMC1723406
Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil
E. Midena, C. D. Angeli, M. Valenti, V. de Belvis, and P. Boccato
Ocular Oncology Service, Institute of Ophthalmology, University of Padua, Padua, Italy.
Abstract
AIM—To evaluate the efficacy of topical 5-fluorouracil (5-FU) alone, without concurrent surgery or radiotherapy, for the treatment of conjunctival squamous cell carcinoma.
METHODS—Eight patients affected by conjunctival squamous cell carcinoma (three recurrent cases, three incompletely excised, and two untreated cases) were treated with 1% 5-FU eye drops. Topical 1% 5-FU was administered four times daily for 4 weeks (one course). Clinical examination (biomicroscopy and photography) and morphological evaluation of conjunctival cytological specimens were used to monitor the efficacy of local chemotherapy, side effects, and recurrences.
RESULTS—All patients showed clinical regression of conjunctival carcinoma after topical 1% 5-FU treatment. Neoplastic conjunctiva was completely replaced by normal epithelium within 3 months. Mean follow up was 27 months. One patient needed two courses of local chemotherapy for recurrent disease. An acute transient toxic keratoconjunctivitis was observed in all treated cases; it was easily controlled with topical therapy. No long term side effects were found.
CONCLUSIONS—Topical 1% 5-FU is effective in the treatment of recurrent, incompletely excised, and selected untreated conjunctival squamous cell carcinomas. Topical 1% 5-FU has no major complications. This study suggests that topical conjunctival chemotherapy with 1% 5-FU may be useful, at least as adjunctive therapy, in the treatment of conjunctival squamous cell carcinoma.

Full Text
The Full Text of this article is available as a PDF (170K).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture. Arch Ophthalmol. 1997 Jun;115(6):808–815. [PubMed]
  • Erie JC, Campbell RJ, Liesegang TJ. Conjunctival and corneal intraepithelial and invasive neoplasia. Ophthalmology. 1986 Feb;93(2):176–183. [PubMed]
  • Tabin G, Levin S, Snibson G, Loughnan M, Taylor H. Late recurrences and the necessity for long-term follow-up in corneal and conjunctival intraepithelial neoplasia. Ophthalmology. 1997 Mar;104(3):485–492. [PubMed]
  • Lommatzsch P. Beta-ray treatment of malignant epithelial tumors of the conjunctiva. Am J Ophthalmol. 1976 Feb;81(2):198–206. [PubMed]
  • Frucht-Pery J, Rozenman Y. Mitomycin C therapy for corneal intraepithelial neoplasia. Am J Ophthalmol. 1994 Feb 15;117(2):164–168. [PubMed]
  • Yeatts RP, Ford JG, Stanton CA, Reed JW. Topical 5-fluorouracil in treating epithelial neoplasia of the conjunctiva and cornea. Ophthalmology. 1995 Sep;102(9):1338–1344. [PubMed]
  • Frucht-Pery J, Pe'er J. Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia. Arch Ophthalmol. 1996 Oct;114(10):1261–1264. [PubMed]
  • Frucht-Pery J, Sugar J, Baum J, Sutphin JE, Pe'er J, Savir H, Holland EJ, Meisler DM, Foster JA, Folberg R, Rozenman Y. Mitomycin C treatment for conjunctival-corneal intraepithelial neoplasia: a multicenter experience. Ophthalmology. 1997 Dec;104(12):2085–2093. [PubMed]
  • Wilson MW, Hungerford JL, George SM, Madreperla SA. Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. Am J Ophthalmol. 1997 Sep;124(3):303–311. [PubMed]
  • Heigle TJ, Stulting RD, Palay DA. Treatment of recurrent conjunctival epithelial neoplasia with topical mitomycin C. Am J Ophthalmol. 1997 Sep;124(3):397–399. [PubMed]
  • de Keizer RJ, de Wolff-Rouendaal D, van Delft JL. Topical application of 5-fluorouracil in premalignant lesions of cornea, conjunctiva and eyelid. Doc Ophthalmol. 1986 Dec 30;64(1):31–42. [PubMed]
  • Finger PT, Milner MS, McCormick SA. Topical chemotherapy for conjunctival melanoma. Br J Ophthalmol. 1993 Nov;77(11):751–753. [PubMed]
  • Grossniklaus HE, Aaberg TM., Sr Mitomycin C treatment of conjunctival intraepithelial neoplasia. Am J Ophthalmol. 1997 Sep;124(3):381–383. [PubMed]
  • Midena E, Boccato P, Angeli CD. Conjunctival squamous cell carcinoma treated with topical 5-fluorouracil. Arch Ophthalmol. 1997 Dec;115(12):1600–1601. [PubMed]
  • Gelender H, Forster RK. Papanicolaou cytology in the diagnosis and management of external ocular tumors. Arch Ophthalmol. 1980 May;98(5):909–912. [PubMed]
  • Paridaens AD, McCartney AC, Curling OM, Lyons CJ, Hungerford JL. Impression cytology of conjunctival melanosis and melanoma. Br J Ophthalmol. 1992 Apr;76(4):198–201. [PubMed]
  • Midena E, Segato T, Blarzino MC. Effects of ionizing radiation on human conjunctival epithelial cells: a clinical and cytologic study. Ophthalmologica. 1991;203(2):75–81. [PubMed]
Figures and Tables
Figure 1
Figure 1
Figure 1  
Conjunctival cytological smears of a case of recurrent squamous cell carcinoma: the picture is consistent with moderately differentiated squamous cell carcinoma (Papanicolaou, original magnification ×125 (left) and ×240 (right)).
Figure 2
Figure 2
Figure 2  
Conjunctival cytological smears obtained 3 months after the end of one course of 5- fluorouracil (in the same patient and conjunctival area of Fig 1) show normal conjunctival epithelial cells (Papanicolaou, original magnification ×125 (more ...)
Figure 3
Figure 3
Figure 3  
Histopathological specimens of a conjunctival biopsy in a case of recurrent squamous cell carcinoma (haematoxylin and eosin, original magnification ×180 (left) and ×240 (right)).
Figure 4
Figure 4
Figure 4  
Histopathological specimen of the case shown in Figure 3, 23 months after the end of 5-fluorouracil topical treatment. Normal conjunctiva has replaced the carcinomatous area (haematoxylin and eosin, original magnification ×125).
Figure 5
Figure 5
Figure 5  
Clinical picture of a diffuse conjunctival squamous cell carcinoma (case 2; Table 1) before treatment with topical 1% 5-fluorouracil.
Figure 6
Figure 6
Figure 6  
The conjunctiva in the same area as shown in Figure 5, 3 months after the end of treatment with 5-fluorouracil. No clinical signs of the lesion are present.